Book a FREE consultation  
For a free consultation or assistance, please call 020 7730 6666

Browse by Category

“Will Tofacitinib Citrate (Xeljanz) Cure My Son’s Alopecia Universalis?”

hairlossANSWERS - you ask, our hair loss experts answer
Mr. H. Korkmaz

Question: My son has alopecia universalis one year. We live in Holland. I read about tofacitinib citrate that have a cure for alopecia. We want to come to London to treat my son, we want to make an appointment.

Answer: Tofacitinib citrate, more commonly known by its brand name of Xeljanz, is a rheumatoid arthritis drug currently in testing for the treatment of alopecia conditions after a recent Yale University study successfully used the drug to treat an alopecia universalis sufferer. The patient, a 25 year old male who was initially referred to the medical facility for the skin condition plaque psoriasis, experienced excellent regrowth results over the course of the 8 month-long study.

Arthritis Drug Used to Treat Hair Loss from Alopecia Universalis in Yale University Study

Arthritis Drug Used to Treat Hair Loss from Alopecia Universalis in Yale University Study

However, whilst the signs from the Yale University study were certainly promising, and the drug has previously been used to successfully treat psoriasis in humans and to reverse lesser forms of alopecia in mice, the serious side effects of Xeljanz as a treatment for arthritis are alarming and definitely warrant further investigation.

Tofacitinib is an immunosuppressant that works by damping down the immune system so the progress and symptoms of diseases caused by the body’s own immune system attacking it can be slowed and relieved. The problem is that this means the body is not protected from opportunistic infections, and cancers are more likely to develop in the long term. The drug is currently undergoing clinical trials into its long-term safety.

At the moment Xeljanz is FDA-approved for the treatment of rheumatoid arthritis in the USA, with similar usage-approvals granted in Argentina, Columbia, Kuwait, the United Arab Emirates, Russia and Switzerland. Japan has also approved tofacitinib citrate for this type of treatment in adults, although there it has the brand name Jaquinus.

Tofacitinib Citrate is presently unavailable in the UK as it has not been granted a license by the Medicines and Healthcare products Regulatory Agency (MHRA), due in part to concerns about the incidences of serious side-effects such as cancers, infections and digestive tract problems.

As testing is still in the early stages, the dose which may be effective for alopecia totalis and universalis has not yet been fully established, so the adverse effect profile may improve but it is too early to speculate either way.

Depending on his age, you may want to explore Topical Immunotherapy for your son as a potential alternative, although it is controversial for children to undergo this treatment. It works by creating an allergic reaction on affected areas of skin, shocking the hair follicles into production. Topical Immunotherapy is currently considered the most effective treatment for alopecia universalis available, with a success rate of around 40% although treatment does need to be sustained in order for hair growth to continue. There have also been reports of unpleasant side effects from this form of treatment.

The range of known adverse effects from Topical Immunotherapy includes persistent dermatitis, generalized eczema, blistering, contact leukoderma, urticarial reaction and vitiligo, a condition which causes a patchy discolouration of the skin.

For support and information on dealing with alopecia universalis, we recommend you contact Alopecia WorldAlopecia World is a social network for both adults and children experiencing alopecia. The site has hundreds of users and offers a chance for your son to meet other people with the same condition as him.

Circ The Belgravia Centre Hair Loss Treatment for Alopecia AreataThe Belgravia Centre

The Belgravia Centre is the leader in hair loss treatment in the UK, with two clinics based in Central London. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the UK or the rest of the world. View our Hair Loss Success Stories, which are the largest collection of such success stories in the world and demonstrate the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time for our hair loss helpline or to arrange a free consultation.

Related Stories

Share this article

No Comments

No comments yet.

Comment on this article

* required field

Will not be published

Online Consultation

Submit an instant online consultation so that one of Belgravia’s hair loss specialists can diagnose your condition and recommend an effective course of treatment, wherever you live.

26 Apr

BGT Winner Says Street Dance Headspin Moves Caused Hair Loss

The soaring popularity of street dance has become something of a phenomenon across the UK in recent years. This has been helped in part by its heightened visibility thanks to acts like Diversity and George Sampson, both winners of the high profile TV talent show, Britain’s Got Talent, who have gone on to have successful […]

Read full article »
25 Apr

Success Story Alert! New Female Hair Loss Treatment Entry

A new entry has just been added to Belgravia’s Female Pattern Hair Loss Treatment Success Stories gallery. Miss D has seen positive results in all thinning areas since she started using her bespoke Belgravia treatment plan. Find out what this client had to say and see her regrowth results close up, or find out more about treating […]

Read full article »
25 Apr

What is Invisible Hair Loss and How Do You Tell if You Have it?

In what could be the oddest bit of “rebranding” for some time, an article on a US website has given a new name to the genetic hair loss condition, Male Pattern Baldness. The Fox News website explains how a typical healthy scalp has around 100,000 hairs and that around half of these can be lost before […]

Read full article »